Publications 2011-

 Original articles:

  1. Kari-Pekka Skarp, Ayda Shams, Hanna Montelin, Pernilla Lagerbäck, Thomas Tängdén. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against ESBL-producing Escherichia coli in 24-h time-kill experiments, International Journal of Antimicrobial Agents, 2018, 

  2. W. Ungphakorn, P. Lagerbäck, E.I. Nielsen, T. Tängdén. Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria. Clinical Microbiology and Infection, Volume 24, Issue 7, 2018, Pages 778.e7-778.e14,
  3. Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O. Reply to Prim et al., "Is Colistin Susceptibility Testing Finally on the Right Track?" Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02507-17. doi: 10.1128/AAC.02507-17.

  4. Thomas Tängdén, Céline Pulcini, Helle Aagaard, Manica Balasegaram, Gabriel Levy Hara, Dilip Nathwani, Mike Sharland, Ursula Theuretzbacher, Otto Cars. Unavailability of old antibiotics threatens effective treatment for common bacterial infections. The Lancet Infectious Diseases, Volume 18, Issue 3, 2018, Pages 242-244,

  5. Rochford C, Sridhar D, Woods N, Saleh Z, Hartenstein L, Ahlawat H, Whiting E, Dybul M, Cars O, Goosby E, Cassels A, Velasquez G, Hoffman S, Baris E, Wadsworth J, Gyansa-Lutterodt M, Davies S. Global governance of antimicrobial resistance. Lancet. 2018 May 19;391(10134):1976-1978. doi: 10.1016/S0140-6736(18)31117-6

  6. Tängdén, T., Cojutti, P.G., Roberts, J.A. et al. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. Clin Pharmacokinet (2018),

  7. David D. Khan, Pernilla Lagerbäck, Christer Malmberg, Anders N. Kristoffersson, Erik Wistrand-Yuen, Cao Sha, Otto Cars, Dan I. Andersson, Diarmaid Hughes, Elisabet I. Nielsen, Lena E. Friberg. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli. International Journal of Antimicrobial Agents Volume 51, Issue 3, March 2018, Pages 399-406,

  8. Karvanen, M., Malmberg, C., Lagerbäck, P., Friberg, L., Cars, O. Colistin is Extensively Lost during Standard in Vitro Experimental Conditions. Antimicrobial Agents and Chemotherapy 2017 61(11). doi: 10.1128/AAC.00857-17

  9. Ungphakorn W, Malmberg C, Lagerbäck P, Cars O, Nielsen EI, Tängdén T. Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics. J Microbiol Methods. 2017 Jan;132:69-75.

  10. Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis. 2017;6:1-7.

  11. Malmberg C, Yuen P, Spaak J, Cars O, Tängdén T, Lagerbäck P. A Novel Microfluidic Assay for Rapid Phenotypic Antibiotic Susceptibility Testing of Bacteria Detected in Clinical Blood Cultures. PLoS One. 2016 Dec 14;11(12):e0167356.

  12. Ungphakorn W, Tängdén T, Sandegren L, Nielsen EI. A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure. J Antimicrob Chemother. 2016 Sep;71(9):2521-33.

  13. Lagerbäck P, Khine WW, Giske CG, Tängdén T. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments. J Antimicrob Chemother. 2016 Jun;71:2321-5.

  14. Mohamed AF, Kristoffersson AN, Karvanen M, Nielsen EI, Cars O, Friberg LE. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model. J Antimicrob Chemother. 2016 May;71(5):1279-90.

  15. Komp Lindgren P, Higgins PG, Seifert H, Cars O. Prevalence of hypermutators among clinical Acinetobacter baumannii isolates. J Antimicrob Chemother. 2016 Mar;71(3):661-5.

  16. Jonsson AK, Larsson A, Tängdén T, Melhus Å, Lannergård A. A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases. Infect Ecol Epidemiol. 2015 Nov 9;5:28224.

  17. Khan DD, Lagerbäck P, Cao S, Lustig U, Nielsen EI, Cars O, Hughes D, Andersson DI, Friberg LE. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. J Antimicrob Chemother. 2015 Sep 7 (Epub ahead of print).

  18. Sütterlin S, Edquist P, Sandegren L, Adler M, Tängdén T, Drobni M, Olsen B, Melhus A. Silver Resistance Genes are Overrepresented Among Escherichia coli Isolates with CTX-M-production.Appl Environ Microbiol. Appl Environ Microbiol. 2014 Nov;80(22):6863-9.

  19. Marcusson LL, Komp Lindgren P, Olofsson SK, Hughes D, Cars O. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility. Int J Antimicrob Agents. 2014 Oct;44(4):354-7.

  20. Mohamed AF, Cars O, Friberg LE. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J Antimicrob Chemother. 2014 May;69(5):1350-61.

  21. Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58(3):1757-62.

  22. Hickman RA, Hughes D, Cars T, Malmberg C, Cars O. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Clin Microbiol Infect. 2014 Apr;20(4):O267-73.

  23. Ljungquist O, Kjölvmark C, Tängdén T. Carbapenem-resistant Escherichia coli now exist in Sweden. Lakartidningen. 2013 Aug 7-20;110(32-33):1401-2. Swedish.

  24. Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. Journal of Antimicrobial Chemotherapy, 2013 Jun;68(6):1319-26. Epub 2013 Mar 10.

  25. Matti Karvanen, Diamantis Plachouras, Lena E. Friberg, Elisabeth Paramythiotou, Evangelos Papadomichelakis, Ilias Karaiskos, Iraklis Tsangaris, Apostolos Armaganidis, Otto Cars and Helen Giamarellou. Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrob. Agents Chemother. 2013 Jan;57(1):668-71.

  26. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9. Epub 2012 May 21.

  27. Mohamed AF, Nielsen EI, Cars O, Friberg LE. Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother. 2012 Jan;56(1):179-88.

  28. Tängdén T, Enblad P, Ullberg M, Sjölin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis. 2011 Jun;52(11):1310-6.

  29. Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30.

  30. Lignell A, Löwdin E, Cars O, Chryssanthou E, Sjölin J. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother. 2011 Jul;55(7):3099-104.

  31. Tängdén T, Eriksson BM, Melhus A, Svennblad B, Cars O. Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011 May;66(5):1161-7.

  32. Lignell A, Löwdin E, Cars O, Sanglard D, Sjölin J. Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone. Antimicrob Agents Chemother. 2011 Apr;55(4):1629-37.

  33. Nielsen EI, Cars O, Friberg LE. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2011 Apr;55(4):1571-9.



 Review articles:

  1. Prof Evelina Tacconelli MD, Elena Carrara MD, Alessia Savoldi MD, Prof Stephan Harbarth MD, Prof Marc Mendelson MD, Dominique L Monnet PhD, Prof Céline Pulcini MD, Prof Gunnar Kahlmeter MD, Prof Jan Kluytmans MD, Prof Yehuda Carmeli MD, Prof Marc Ouellette MD, Prof Kevin Outterson JD, Jean Patel PhD, Marco Cavaleri PhD, Edward M Cox MD, Chris R Houchens PhD, Prof M Lindsay Grayson MD, Prof Paul Hansen PhD, Prof Nalini Singh MD, Ursula Theuretzbacher PhD, Nicola Magrini MD and the WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious DiseasesVolume 18, Issue 3, March 2018, Pages 318-327

  2. Tängdén T, Pulcini C, Aagard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O. Unavailability of old antibiotics threatens effective treatment for common bacterial infections. Lancet Infect Dis. 2018 Mar;18(3):242-244. doi: 10.1016/S1473-3099(18)30075-6.

  3. Mölstad S, Löfmark S, Carlin K, Erntell M, Aspevall O, Blad L, Hanberger H, Hedin K, Hellman J, Norman C, Skoog G, Stålsby-Lundborg C, Tegmark Wisell K, Åhrén C, Cars O. Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance. Bull World Health Organ. 2017 Nov 1;95(11):764-773. doi:10.2471/BLT.16.184374.

  4. Pulcini, C., Beovic, B., Beraud, G., Carlet, J., Cars, O. et al. Ensuring universal access to old antibiotics: a critical but neglected priority. Clinical Microbiology and Infection 2017 23(9): 590-592.

  5. Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics. Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents. 2017 Jan;49(1):98-101.

  6. Dittrich S, Tadesse BT, Moussy F, Chua A, Zorzet A, Tängdén T, Dolinger DL, Page AL, Crump JA, D'Acremont V, Bassat Q, Lubell Y, Newton PN, Heinrich N, Rodwell TJ, González IJ. Target Product Profile for a Diagnostic Assay to Differentiate between Bacterial and Non-Bacterial Infections and Reduce Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus. PLoS One. 2016 Aug 25;11(8):e0161721.

  7. Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance-a threat to the world's sustainable development. Ups J Med Sci. 2016 Aug;121(3):159-64.

  8. Laxminarayan R, Amábile-Cuevas CF, Cars O, Evans T, Heymann DL, Hoffman S, Holmes A, Mendelson M, Sridhar D, Woolhouse M, Røttingen JA. UN High-Level Meeting on antimicrobials--what do we need? Lancet. 2016 Jul 16;388(10041):218-20.

  9. Skoog G, Struwe J, Cars O, Hanberger H, Odenholt I, Prag M, Skärlund K, Ulleryd P, Erntell M. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: data for actions 2003-2010. Euro Surveill. 2016 Jun 23;21(25).

  10. Littmann J, Buyx A, Cars O. Antibiotic resistance: An ethical challenge. Int J Antimicrob Agents. 2015 July (Epub ahead of print).

  11. Daulaire N, Bang A, Tomson G, Kalyango JN, Cars O. Universal Access to Effective Antibiotics is Essential for Tackling Antibiotic Resistance. J Law Med Ethics. 2015 Jun;43 Suppl 3:17-21.

  12. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015 May;277(5):501-12.

  13. Cars O. Enkla åtgärder i landstingen kan ge säkrare behandling vid sepsis - Tidig diagnos avgörande - laboratorier måste hantera blododlingar snabbare. Lakartidningen. 2015 Feb 10;112.

  14. Tängden T, Furebring M, Löwdin E, Werner S. Cross sensitivity to other betalactams in patients with allergy to penicillin less frequent that previously believed. Lakartidningen. 2015 Feb 3;112.

  15. Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015 Feb 1;93(2):66.

  16. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb;15(2):225-34.

  17. Högberg LD, Muller A, Zorzet A, Monnet DL, Cars O. Antibiotic use worldwide. Lancet Infect Dis. 2014 Dec;14(12):1179-80.

  18. Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med. 2014 Nov 6;371(19):1761-3.

  19. Tängdén T. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci. 2014 May;119(2):149-53.

  20. Cars O. Securing access to effective antibiotics for current and future generations. Whose responsibility? Ups J Med Sci. 2014 May;119(2):209-14.

  21. Heyman G, Cars O, Bejarano MT, Peterson S. Access, excess, and ethics-towards a sustainable distribution model for antibiotics. Ups J Med Sci. 2014 May;119(2):134-41.

  22. Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J, Cars O. Global survey of polymyxin use: A call for international guidelines. J Glob Antimicrob Resist. 2013 Sep;1(3):131-134.

  23. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057-98.

  24. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan;58(1):139-41.

  25. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012 Apr 3;344.


61094 UU logo tranp4f125px


The Antibiotic research unit,

Department of Medical Sciences

Uppsala University Hospital

Clinical microbiology, Hubben, 5th floor

S-751 85  Uppsala


Visiting Address

The Antibiotic research unit

Hubben, 5th floor

Dag Hammarskjölds v. 38

752 37 Uppsala



Pernilla Lagerbäck: +46(0)18 611 34 80